TCT-40 Medication Use and 3-Year Mortality After Transcatheter Aortic Valve Replacement (TAVR): Findings From Real-World Claims Data

MLA

Santiago Garcia, et al. “TCT-40 Medication Use and 3-Year Mortality After Transcatheter Aortic Valve Replacement (TAVR): Findings From Real-World Claims Data.” Journal of the American College of Cardiology, vol. 78, Nov. 2021, pp. B16–17. EBSCOhost, https://doi.org/10.1016/j.jacc.2021.09.890.

APA

Santiago Garcia, Shannon Murphy, Juan F. Granada, Martin B. Leon, Megan Coylewright, Craig R. Asher, Philippe Généreux, Brian R. Lindman, Pradeep Yadav, Creighton W. Don, Eduardo Perez, Rebecca T. Hahn, Robert Cubeddu, Vinod H. Thourani, Omar K. Khalique, & João L. Cavalcante. (2021). TCT-40 Medication Use and 3-Year Mortality After Transcatheter Aortic Valve Replacement (TAVR): Findings From Real-World Claims Data. Journal of the American College of Cardiology, 78, B16–B17. https://doi.org/10.1016/j.jacc.2021.09.890

Chicago

Santiago Garcia, Shannon Murphy, Juan F. Granada, Martin B. Leon, Megan Coylewright, Craig R. Asher, Philippe Généreux, et al. 2021. “TCT-40 Medication Use and 3-Year Mortality After Transcatheter Aortic Valve Replacement (TAVR): Findings From Real-World Claims Data.” Journal of the American College of Cardiology 78 (November): B16–17. doi:10.1016/j.jacc.2021.09.890.